Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CD7-H52H3 | Human | Human CD37 Protein, His Tag | ![]() |
![]() ![]() |
|
CD7-HF26x | Human | FITC-Labeled Human CD37 Protein, Fc Tag | ![]() |
![]() ![]() |
|
CD7-H525a | Human | Human CD37 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
|
CD7-H526x | Human | Human CD37 Protein, Fc Tag | ![]() |
![]() ![]() |
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
CAR-37 T cell therapy (Massachusetts General Hospital) | Phase 1 Clinical | Massachusetts General Hospital | Leukemia; Lymphoma, B-Cell; Hematologic Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell | Details | |
AGS-67E | AGS-67E | Phase 1 Clinical | Agensys | Leukemia, Hairy Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Lutetium (177lu) lilotomab satetraxetan | 177Lu-DOTA-HH1 | Phase 2 Clinical | Nordic Nanovector | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
BI-836826 | mAb-37.1; mAb-37.2; BI-836826 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Naratuximab emtansine | IMGN-529; K7153A-SMCC-DM1 | Phase 2 Clinical | Immunogen | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Ivicentamab | GEN-3009 | Phase 2 Clinical | Genmab, Abbvie Inc | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
This web search service is supported by Google Inc.